The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non–Small-Cell Lung Cancer
Abstract
PURPOSE: To determine the safety and tolerability of adenovirus-mediated p53 (Adp53) gene transfer in sequence with cisplatin when given by intratumor injection in patients with non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with advanced NSCLC and abnormal p53 function were enrolled onto cohorts receiving escalating dose levels of Adp53 (1 × 10 6 to 1 × 10 11 plaque-forming units [PFU]). Patients were administered intravenous cisplatin 80 mg/m 2 on day 1 and study vector on day 4 for a total of up to six courses (28 days per course). Apoptosis was determined by the terminal deoxynucleotidyl- transferase-dUTP nick–end labeling assay. Evidence of vector-specific sequences were determined using reverse-transcriptase polymerase chain reaction. Vector dissemination and biodistribution was monitored using a series of assays (cytopathic effects assay, Ad5 hexon enzyme-linked immunosorbent assay, vector-specific polymerase chain reaction assay, and antibody response assay). RESULTS: Twenty-four patients (median age, 64 years) received a total of 83 intratumor injections with Adp53. The maximum dose administered was 1 × 10 11 PFU per dose. Transient fever related to Adp53 injection developed in eight of 24 patients. Seventeen patients achieved a best clinical response of stable disease, two patients achieved a partial response, four patients had progressive disease, and one patient was not assessable. A mean apoptotic index between baseline and follow-up measurements increased from 0.010 to 0.044 (P = .011). Intratumor transgene mRNA was identified in 43% of assessable patients. CONCLUSION: Intratumoral injection with Adp53 in combination with cisplatin is well tolerated, and there is evidence of clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment
Wickham, T. J., Mathias, P., Cheresh, D. A., & Nemerow, G. R. (1993) · Cell · doi:10.1016/0092-8674(93)90231-e · Cited by 2,199
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,003
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
Clinical Implications of the p53 Tumor-Suppressor Gene
Harris, C. C., & Hollstein, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,330
Roth, J. A., Fossella, F., Komaki, R., Ryan, M. B., Putnam, J. B., Lee, J. S., Dhingra, H., De Caro, L., Chasen, M., McGavran, M., et al. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.9.673 · Cited by 1,111
Self-citationRosenfeld, M. A., Yoshimura, K., Trapnell, B. C., Yoneyama, K., Rosenthal, E. R., Dalemans, W., Fukayama, M., Bargon, J., Stier, L. E., Stratford-Perricaudet, L., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90213-v · Cited by 931
Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A. W., Brown, R. W., Chamness, G. C., Osborne, C. K., & McGuire, W. L. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.3.200 · Cited by 772
An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain
La Salle, G. L. G., Robert, J. J., Berrard, S., Ridoux, V., Stratford-Perricaudet, L. D., Perricaudet, M., & Mallet, J. (1993) · Science · doi:10.1126/science.8382374 · Cited by 738
Thor, A. D., Moore, D. H., Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L.-C., Mayall, B. H., et al. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.11.845 · Cited by 723
Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer.
Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., Hong, W. K., Komaki, R., Lee, J. J., Nesbitt, J. C., et al. (1996) · Nature Medicine · doi:10.1038/nm0996-985 · Cited by 703
Self-citationClonal expansion of p53 mutant cells is associated with brain tumour progression
Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M. L., Cavanee, W., & Vogelstein, B. (1992) · Nature · doi:10.1038/355846a0 · Cited by 670
Adenoviruses in the immunocompromised host
Hierholzer, J. C. (1992) · Clinical Microbiology Reviews · doi:10.1128/cmr.5.3.262 · Cited by 587
Chiba, I., Takahashi, T., Nau, M. M., D'Amico, D., Dt, C., Mitsudomi, T., Buchhagen, D. L., Carbone, D. P., Piantadosi, S., & KOGA, H. (1990) · PubMed · Cited by 514
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. G., El-Naggar, A. K., Fossella, F., Glisson, B. S., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.9.763 · Cited by 496
Self-citationFujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen‐Schaub, L. B., & Roth, J. A. (1994) · PubMed · Cited by 464
Self-citationEfficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice
Ragot, T., Vincent, N., Chafey, P., Vigne, E., Gilgenkrantz, H., Coutont, D., Cartaud, J., Briand, P., Kaplant, J.-C., Perricaude, M., et al. (1993) · Nature · doi:10.1038/361647a0 · Cited by 457
Adenovirus–mediated in vivo gene transfer and expression in normal rat liver
Jaffe, H. A., Danel, C., Longenecker, G., Metzger, M., Setoguchi, Y., Rosenfeld, M. A., Gant, T. W., Thorgeirsson, S. S., Stratford-Perricaudet, L. D., Perricaudet, M., et al. (1992) · Nature Genetics · doi:10.1038/ng0892-372 · Cited by 449
Bursch, W., Paffe, S., Putz, B., Barthel, G., & Schulte-Hermann, R. (1990) · Carcinogenesis · doi:10.1093/carcin/11.5.847 · Cited by 444
Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization.
Wickham, T. J., Filardo, E. J., Cheresh, D. A., & Nemerow, G. R. (1994) · The Journal of cell biology · doi:10.1083/jcb.127.1.257 · Cited by 417
Survival in early-stage non-small cell lung cancer
Nesbitt, J. C., Putnam, J. B., Walsh, G. L., Roth, J. A., & Mountain, C. F. (1995) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00169-l · Cited by 383
Self-citationAccumulation of p53 protein correlates with a poor prognosis in human lung cancer.
Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., & Doshi, H. M. (1992) · PubMed · Cited by 383
Clayman, G. L., el-Naggar, A. K., Lippman, S. M., Henderson, Y. C., Frederick, M., Merritt, J. A., Zumstein, L. A., Timmons, T. M., Liu, T. J., Ginsberg, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2221 · Cited by 371
Self-citation(1992) · American Journal of Otolaryngology · doi:10.1016/0196-0709(92)90038-u · Cited by 350
Stratford-Perricaudet, L. D., Levrero, M., Chasse, J.-F., Perricaudet, M., & Briand, P. (1990) · Human Gene Therapy · doi:10.1089/hum.1990.1.3-241 · Cited by 325
Adenovirus-Mediated Transfer of the CFTR Gene to Lung of Nonhuman Primates: Toxicity Study
Simon, R. H., Engelhardt, J. F., Yang, Y., Zepeda, M., Weber-Pendleton, S., Grossman, M., & Wilson, J. M. (1993) · Human Gene Therapy · doi:10.1089/hum.1993.4.6-771 · Cited by 323
p53 expression and prognosis in gastric carcinoma
Martin, H. M., Filipe, M. I., Morris, R. W., Lane, D. P., & Silvestre, F. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500604 · Cited by 321
The biochemistry of cell death by apoptosis
Bursch, W., Kleine, L., & Tenniswood, M. (1990) · Biochemistry and Cell Biology · doi:10.1139/o90-160 · Cited by 318
Multiple adenovirus serotypes use alpha v integrins for infection
Mathias, P., Wickham, T., Moore, M., & Nemerow, G. (1994) · Journal of Virology · doi:10.1128/jvi.68.10.6811-6814.1994 · Cited by 286
Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM.
Enoch, T., & Norbury, C. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89093-3 · Cited by 261
Zhang, W. W., Fang, X., Mazur, W. M., French, B. A., Georges, R. N., & Roth, J. A. (1994) · PubMed · Cited by 257
Self-citationBouvet, M., Ellis, L. M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C. D., Fang, B., Lee, J. J., & Roth, J. A. (1998) · PubMed · Cited by 242
Self-citationGómez-Foix, A. M., Coats, W. S., Baqué, S., Alam, T., Gerard, R. D., & Newgard, C. B. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74015-0 · Cited by 241
Wills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M.-T., Huang, W.-M., Johnson, D. E., Anderson, S. C., Wen, S. F., et al. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.9-1079 · Cited by 233
Engelhardt, J. F., Simon, R. H., Yang, Y., Zepeda, M., Weber-Pendleton, S., Doranz, B., Grossman, M., & Wilson, J. M. (1993) · Human Gene Therapy · doi:10.1089/hum.1993.4.6-759 · Cited by 195
Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus)
Prince, G. A., Porter, D. D., Jenson, A. B., Horswood, R. L., Chanock, R. M., & Ginsberg, H. S. (1993) · Journal of Virology · doi:10.1128/jvi.67.1.101-111.1993 · Cited by 177
Abratt, R. P., Bezwoda, W. R., Goedhals, L., & Hacking, D. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.744 · Cited by 177
Yei, S., Mittereder, N., Wert, S., Whitsett, J. A., Wilmott, R. W., & Trapnell, B. C. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.6-731 · Cited by 172
Nuclear p53 Immunoreaction Associated with Poor Prognosis of Breast Cancer
Iwaya, K., Tsuda, H., Hiraide, H., Tamaki, K., Tamakuma, S., Fukutomi, T., Mukai, K., & Hirohashi, S. (1991) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1991.tb02710.x · Cited by 171
Development and Analysis of Recombinant Adenoviruses for Gene Therapy of Cystic Fibrosis
Rich, D. P., Couture, L. A., Cardoza, L. M., Guiggio, V. M., Armentano, D., Espino, P. C., Hehir, K., Welsh, M. J., Smith, A. E., & Gregory, R. J. (1993) · Human Gene Therapy · doi:10.1089/hum.1993.4.4-461 · Cited by 162
Crook, T., & Vousden, K. H. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05487.x · Cited by 148
Lesoon‐Wood, L. A., Kim, W. H., Kleinman, H. K., Weintraub, B. D., & Mixson, A. J. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.4-395 · Cited by 142
Mittal, S. K., McDermott, M. R., Johnson, D. C., PREVEC, L., & Graham, F. L. (1993) · Virus Research · doi:10.1016/0168-1702(93)90090-a · Cited by 140
Nguyen, D. M., Spitz, F. R., Yen, N., Cristiano, R. J., & Roth, J. A. (1996) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(96)70154-x · Cited by 137
Self-citationInst., H. (1994) · Lung Cancer · doi:10.1016/0169-5002(94)90782-x · Cited by 132
Klastersky, J. A., Sculier, J., Bureau, G., Libert, P., Ravez, P., Vandermoten, G., Thiriaux, J., Lecomte, J., Cordier, R., & Dabouis, G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1087 · Cited by 130
Cai, D. W., Mukhopadhyay, T., Liu, Y., Fujiwara, T., & Roth, J. A. (1993) · Human Gene Therapy · doi:10.1089/hum.1993.4.5-617 · Cited by 124
Self-citationSomatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius, S., Børresen‐Dale, A., & Eyfjörd, J. E. (1993) · PubMed · Cited by 119
Safety Evaluation of Ad5CMY- p53 In Vitro and In Vivo
Zhang, W., Alemany, R., Wang, J., Koch, P. E., Ordóǹez, N. G., & Roth, J. A. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.2-155 · Cited by 119
Self-citationHamada, M., Fujiwara, T., HIZUTA, A., Gochi, A., Naomoto, Y., Takakura, N., Takahashi, K., Roth, J. A., Tanaka, N., & Orita, K. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01220804 · Cited by 115
Self-citationEfficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts.
Ll, N., Dell, J., Maxwell, E., et al. (1997) · PubMed · Cited by 114
Bártek, J., Bártková, J., Lukáš, J., Stašková, Z., Vojtěšek, B., & Lane, D. P. (1993) · The Journal of Pathology · doi:10.1002/path.1711690106 · Cited by 90
Xu, L., Pirollo, K. F., & Chang, E. H. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.4-467 · Cited by 88
Takafuji, E. T., Gaydos, J. C., Allen, R. G., & Top, F. H. (1979) · The Journal of Infectious Diseases · doi:10.1093/infdis/140.1.48 · Cited by 85
Role of early genes in pathogenesis of adenovirus pneumonia.
Ginsberg, H. S., Horswood, R. L., Chanock, R. M., & Prince, G. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.16.6191 · Cited by 79
Human adenovirus cloning vectors based on infectious bacterial plasmids
Ghosh-Choudhury, G., Haj-Ahmad, Y., Brinkley, P., Rudy, J., & Graham, F. L. (1986) · Gene · doi:10.1016/0378-1119(86)90321-5 · Cited by 76
Gudas, J. M., Nguyen, H., Klein, R. C., Katayose, D., Seth, P. K., & Cowan, K. H. (1995) · PubMed · Cited by 74
Isobe, T., Hiyama, K., Yoshida, Y., Fujiwara, Y., & Yamakido, M. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02936.x · Cited by 71
Doyne Lecture. Responses of retinal and choroidal vessels to ionising radiation.
Nicholson, F. (1993) · PubMed · doi:10.1038/eye.1993.3 · Cited by 63
Masuda, N., Fukuoka, M., Kudoh, S., Matsui, K., Kusunoki, Y., Takada, M., Nakagawa, K., Hirashima, T., Tsukada, H., & Yana, T. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1833 · Cited by 61
Seth, P. K., Katayose, D., Li, Z., Kim, M., Wersto, R. P., Craig, C., Shanmugam, N., Ohri, E., Mudahar, B., Rakkar, A. N. S., et al. (1997) · PubMed · Cited by 41
Cited by
Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.289 · Cited by 471
Self-citationCurrent Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers
Peng, Z. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1016 · Cited by 436
Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.21.13.2508 · Cited by 395
Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
Edis, Z., Wang, J., Waqas, M. K., Ijaz, M., & Ijaz, M. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s289443 · Cited by 390
TP53 Mutations in Nonsmall Cell Lung Cancer
Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/583929 · Cited by 388
Metadata
- Authors
- Nemunaitis, J., Swisher, S. G., Timmons, T., Connors, D., Mack, M., Doerksen, L., Weill, D., Wait, J., Lawrence, D. D., Kemp, B. L., Fossella, F., Glisson, B. S., Hong, W. K., Khuri, F. R., Kurie, J. M., Lee, J. J., Lee, J. S., Nguyen, D. M., Nesbitt, J. C., Perez-Soler, R., Pisters, K. M. W., Putnam, J. B., Richli, W. R., Shin, D. M., Walsh, G. L., Merritt, J., & Roth, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-02-01
- Volume
- 18
- Issue
- 3
- Pages
- 609-609
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1950719160
- Cited by
- 322
- References
- 66
- FWCI
- 23.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.